BLA 021640 · Bausch and Lomb
Vitrase
Hyaluronidase · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
May 5, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
274
57 Phase 3, 49 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 5, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
2 products under this application
- VITRASE · HYALURONIDASE 6,200 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
- VITRASE · HYALURONIDASE 200 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hyaluronidase" as an intervention, any sponsor and status, largest first.
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06876714 · 1,524 participants (planned) · Start Sep 17, 2025 · Primary completion Mar 13, 2028
Drug: Trastuzumab (Herceptin); Pertuzumab · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2+ Breast Cancer
Sites: Phoenix, Arizona; Fort Smith, Arkansas; Jonesboro, Arkansas · 702 sites in all
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaPivotal-lookingNot yet recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07887984 · 920 participants (planned) · Start Dec 23, 2026 · Primary completion Aug 1, 2033
Drug: Daratumumab and Recombinant Human Hyaluronidase; Lenalidomide and 5 more · For: Multiple Myeloma (MM)
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05020236 · 893 participants (planned) · Start Oct 4, 2021 · Primary completion Feb 26, 2026
Drug: Elranatamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Clovis, California; Fresno, California; Fort Collins, Colorado · 237 sites in all
- Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhagePivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00198510 · 750 participants · Start Nov 1998 · Primary completion Sep 2001
Drug: Vitrase; Vitrase and 1 more · For: Vitreous Hemorrhage; Diabetic Retinopathy
Sites: Tucson, Arizona; Beverly Hills, California; Chula Vista, California · 73 sites in all
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07383441 · 718 participants (planned) · Start Jun 5, 2026 · Primary completion Jan 31, 2033
Drug: Axitinib; Cabozantinib and 7 more · For: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; Rogers, Arkansas · 41 sites in all
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionPivotal-lookingActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT03267433 · 689 participants (planned) · Start Nov 27, 2017 · Primary completion Jan 31, 2027
Drug: Rituximab; Rituximab and Hyaluronidase Human · For: Mantle Cell Lymphoma
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 375 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adverse Events Associated with Hyaluronic Acid Filler Injection for Non-surgical Facial Aesthetics: A Systematic Review of High Level of Evidence Studies.
Kyriazidis I, Spyropoulou GA, Zambacos G, et al. · Aesthetic Plast Surg 2024 · Systematic Review
- Subcutaneous versus intravenous nivolumab for renal cell carcinoma.
Albiges L, Bourlon MT, Chacón M, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Comparative Study
- A Systematic Review on the Effectiveness and Safety of Combining Biostimulators with Botulinum Toxin, Dermal Fillers, and Energy-Based Devices.
Tam E, Choo JPS, Rao P, et al. · Aesthetic Plast Surg 2025 · Systematic Review
- Pain management after elective craniotomy: A systematic review with procedure-specific postoperative pain management (PROSPECT) recommendations.
Mestdagh FP, Lavand'homme PM, Pirard G, et al. · Eur J Anaesthesiol 2023 · Systematic Review
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR, Im SA, Mattar A, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Equivalence Trial
- IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Burotto M, Zvirbule Z, Mochalova A, et al. · Ann Oncol 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.